Fellowship · ATLANTA, GA
Sponsored by Emory University School of Medicine
Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.
The New England journal of medicine · 2022 · 755 citations · Jonathan Glass
Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology.
Nature genetics · 2021 · 434 citations · Jonathan Glass
Mis-spliced transcripts generate de novo proteins in TDP-43-related ALS/FTD.
Science translational medicine · 2024 · 158 citations · Jonathan Glass
Metastatic uveal melanoma: The final frontier.
Progress in retinal and eye research · 2022 · 138 citations · Hans Grossniklaus
Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis.
JAMA neurology · 2026 · 17 citations · Jonathan Glass
Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study.
The Lancet. Neurology · 2024 · 71 citations · Jonathan Glass
Answer ALS, a large-scale resource for sporadic and familial ALS combining clinical and multi-omics data from induced pluripotent cell lines.
Nature neuroscience · 2022 · 124 citations · Jonathan Glass
Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis.
Muscle & nerve · 2021 · 141 citations · Jonathan Glass